Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors

Meier, Reinhard; Piert, Morand; Piontek, Guido; Rudelius, Martina; Oostendorp, Robert A.J.; Senekowitsch–Schmidtke, Reingard; Henning, Tobias D.; Wels, Winfried S.; Uherek, Christoph; Rummeny, Ernst J.; Daldrup-Link, Heike E.

doi:10.1016/j.nucmedbio.2008.02.006

Cited by 65 publications

(74 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The accumulation of these cells in regions of the patient containing inflammation or infection can then be visualized and tracked over time. A similar cell tracking technique is used for PET studies whereby [ 18 F]FDG is loaded into a patient's cells that are then retransferred into the patient and tracked; this method (using [ 18 F]FDG) has been used to noninvasively visualize many different types of cells including leukocytes for tracking infection (354), natural killer cells for tracking specific types of cancer (287), and circulating progenitor cells used in the treatment of acute myocardial infarction (90).…”

Section: Examples Of Cell Tracking Using Molecular Imagingmentioning

confidence: 99%

A Molecular Imaging Primer: Modalities, Imaging Agents, and Applications

James

Gambhir

2012

Physiological Reviews

925

954

View full text Add to dashboard Cite

Molecular imaging is revolutionizing the way we study the inner workings of the human body, diagnose diseases, approach drug design, and assess therapies. The field as a whole is making possible the visualization of complex biochemical processes involved in normal physiology and disease states, in real time, in living cells, tissues, and intact subjects. In this review, we focus specifically on molecular imaging of intact living subjects. We provide a basic primer for those who are new to molecular imaging, and a resource for those involved in the field. We begin by describing classical molecular imaging techniques together with their key strengths and limitations, after which we introduce some of the latest emerging imaging modalities. We provide an overview of the main classes of molecular imaging agents (i.e., small molecules, peptides, aptamers, engineered proteins, and nanoparticles) and cite examples of how molecular imaging is being applied in oncology, neuroscience, cardiology, gene therapy, cell tracking, and theranostics (therapy combined with diagnostics). A step-by-step guide to answering biological and/or clinical questions using the tools of molecular imaging is also provided. We conclude by discussing the grand challenges of the field, its future directions, and enormous potential for further impacting how we approach research and medicine.

show abstract

Section: Examples Of Cell Tracking Using Molecular Imagingmentioning

confidence: 99%

A Molecular Imaging Primer: Modalities, Imaging Agents, and Applications

James

Gambhir

2012

Physiological Reviews

925

954

View full text Add to dashboard Cite

show abstract

“…Magnetic resonance imaging, bioluminescence imaging, and positron emission tomography experiments as well as direct analysis of tumor infiltration revealed rapid and specific accumulation of intravenously injected NK-92 carrying first- and second-generation ErbB2-specific or EpCAM-specific CARs in orthotopic breast and subcutaneous prostate carcinoma xenografts in rodents (55, 63, 64, 67, 73), while parental NK-92 cells showed no tumor homing and were mainly localized to spleen and liver (55). Focused ultrasound has been demonstrated to allow systemically applied CAR NK-92 cells to cross the blood–brain barrier and reach breast cancer brain metastases in a xenograft model in immunocompromised rats (65, 66).…”

Section: In Vivo Antitumor Activity Of Car Nk-92 Cellsmentioning

confidence: 99%

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity

et al. 2017

Self Cite

View full text Add to dashboard Cite

Significant progress has been made in recent years toward realizing the potential of natural killer (NK) cells for cancer immunotherapy. NK cells can respond rapidly to transformed and stressed cells and have the intrinsic potential to extravasate and reach their targets in almost all body tissues. In addition to donor-derived primary NK cells, also the established NK cell line NK-92 is being developed for adoptive immunotherapy, and general safety of infusion of irradiated NK-92 cells has been established in phase I clinical trials with clinical responses observed in some of the cancer patients treated. To enhance their therapeutic utility, NK-92 cells have been modified to express chimeric antigen receptors (CARs) composed of a tumor-specific single chain fragment variable antibody fragment fused via hinge and transmembrane regions to intracellular signaling moieties such as CD3ζ or composite signaling domains containing a costimulatory protein together with CD3ζ. CAR-mediated activation of NK cells then bypasses inhibitory signals and overcomes NK resistance of tumor cells. In contrast to primary NK cells, CAR-engineered NK-92 cell lines suitable for clinical development can be established from molecularly and functionally well-characterized single cell clones following good manufacturing practice-compliant procedures. In preclinical in vitro and in vivo models, potent antitumor activity of NK-92 variants targeted to differentiation antigens expressed by hematologic malignancies, and overexpressed or mutated self-antigens associated with solid tumors has been found, encouraging further development of CAR-engineered NK-92 cells. Importantly, in syngeneic mouse tumor models, induction of endogenous antitumor immunity after treatment with CAR-expressing NK-92 cells has been demonstrated, resulting in cures and long-lasting immunological memory protecting against tumor rechallenge at distant sites. Here, we summarize the current status and future prospects of CAR-engineered NK-92 cells as off-the-shelf cellular therapeutics, with special emphasis on ErbB2 (HER2)-specific NK-92 cells that are approaching clinical application.

show abstract

“…Meller et al reported migration of Indium-labeled NK cells to lung, liver, spleen, and bone marrow [35]. There are reports of successful PET-based imaging of NK cell lines in murine tumor models [36], suggesting that this modality may be applicable to human studies in the future. There is no definitive data regarding whether NK cells cross the blood brain barrier (BBB), although it is known that naive lymphocytes do not cross the BBB, while activated lymphocytes patrol the CNS freely and are actively recruited to sites of inflammation [37].…”

Section: Infusion Of Nk Cells After Transplantmentioning

confidence: 99%

NK Cell Therapy: Targeting Disease Relapse After Hematopoietic Stem Cell Transplantation

et al. 2012

View full text Add to dashboard Cite

Summary As outcomes of hematopoietic stem cell transplantation have improved over time, disease relapse has emerged as the most important causes of treatment failure. Cellular therapy represents a promising therapeutic approach, not only to treat or prevent disease relapse after hematopoietic stem cell transplantation, but also conceivably to help patients achieve remission prior to transplantation or as consolidation therapy for high risk hematologic malignancies. Of the many cellular therapies available, NK cells infusion may be the most promising approach due to strong innate activity of NK cells in vitro and in vivo against malignant or virally infected cells. Published clinical data consists only of small feasibility studies of inadequate size to show clinical benefit. Here we review the current status of clinical investigation using NK cell therapy for patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.

show abstract

Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors

Cited by 65 publications

References 36 publications

A Molecular Imaging Primer: Modalities, Imaging Agents, and Applications

A Molecular Imaging Primer: Modalities, Imaging Agents, and Applications

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity

NK Cell Therapy: Targeting Disease Relapse After Hematopoietic Stem Cell Transplantation

Contact Info

Product

Resources

About